Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Powerball: Oregon authorities reveal winner of $1.3B jackpot
SALEM, Ore. (AP) — One of the winners of a $1.3 billion Powerball jackpot this month is an immigrant2024-04-30100 days since Hamas attacked Israel, triggering war in Gaza
Photo: GIL COHEN-MAGEN / AFP2024-04-30Fire kills 43 in Bangladesh capital
Firefighters work to extinguish a fire in a commercial building that killed at least 43 people, in D2024-04-30EDITORIAL: Sustained wage hike trend also vital for smaller companies
In this year’s “shunto” spring wage negotiations, many major companies have offered higher pay incre2024-04-30- This is the moment a drink-driver nearly swerves into a group of teenage cadets after drinking wine.2024-04-30
Who are the Houthi rebels and why are they attacking Red Sea ships?
Yemen's Houthi loyalists take part in a tribal gathering in Sana'a on 20 February 2020. Photo: AFP2024-04-30
atest comment